Veeva Posts A Solid Q2 Report

Recently re-instated watch list stock Veeva Systems reported its Q2 this week. Sales were up 15%, and profitability rose significantly. This steady and predictable provider of clinical and business software for life sciences firm has a very wide moat and is methodically expanding its product suite into new areas. I love the company but the stock is rarely inexpensive enough to buy. The fair value is $188. After earnings, the stock is trading a good bit above that. We'll leave it on watch.

Watch List

WDAY -13.18%
VEEV 12.52%
PSTG -7.13%
INTU 14.19%
CMG 31.78%
RDDT 7.17%
NTNX 17.22%
CRWD 76.14%
SE 19.26%
SNOW 5.28%
APPF 6.95%

Buy List

PINS -37.54%
ASML -25.06%
SEMR -37.55%
TSM -43.44%
ZETA -32.89%
GOOG -51.47%
NYAX -30.39%
MSFT -31.81%
ODD -32.30%
ASR -26.98%
FLYW -44.52%
HRMY -60.41%
YOU -37.20%
ABNB -33.55%
MELI -26.26%
ADBE -45.26%

Hold List

VTEX -17.92%
CELH 49.08%
TOST 16.30%
CPNG -14.83%
HIMS -23.69%
PAYC -21.14%
MNDY 7.35%
GLBE -24.43%
ZS 23.06%
V -7.38%
ADSK -2.06%
NOW -1.85%
FTNT -4.90%
TEAM -8.65%